Becton Dickinson and Company (BDX) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public…
Total Revenue Chart for Becton Dickinson and Company
Becton Dickinson and Company (BDX) revenue for FY2025 was USD 21.8B, a 8.2% change from FY2024. Becton Dickinson and Company's revenue grew from USD 1.1B in 1985 to USD 21.8B in 2025 (1809.3% over 40 years). Earnings per share grew from USD 1.49 in 2000 to USD 5.84 in 2025 (292.2%). Revenue compound annual growth rate: 5-year CAGR of 6.3%, 10-year CAGR of 7.8%, 20-year CAGR of 7.2%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $49.96B
- Implied Share Price
- $183.40
- Enterprise Value
- $66.05B
- Revenue (TTM)
- $22.48B
- EBITDA
- $6.12B
- Profit Margin
- 4.19%
- Trailing P/E
- 31.73
- Forward P/E
- 13.79
- Price/Book (MRQ)
- 2.05
- Price/Sales (TTM)
- 2.22
- EV/EBITDA
- 13.42
- EV/Revenue
- 2.94
- Dividend Yield
- 2.30%
- Book Value
- $89.64
- Free Cash Flow (FY2025)
- $2.67B
- Free Cash Flow Yield
- 5.34%
Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.